BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Marshall Wace North America L.P.

Marshall Wace North America L.P. grew its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 33.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 540,205 shares of the biotechnology company’s stock after purchasing an additional 135,130 shares during the quarter. Marshall Wace North America L.P. owned approximately 0.30% of BioMarin Pharmaceutical worth $46,270,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the business. BB&T Securities LLC increased its holdings in shares of BioMarin Pharmaceutical by 4.0% in the 2nd quarter. BB&T Securities LLC now owns 3,447 shares of the biotechnology company’s stock valued at $295,000 after acquiring an additional 132 shares during the period. Berman Capital Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical by 56.8% in the 1st quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 151 shares during the period. Avestar Capital LLC increased its holdings in shares of BioMarin Pharmaceutical by 36.9% in the 2nd quarter. Avestar Capital LLC now owns 750 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 202 shares during the period. First Mercantile Trust Co. increased its holdings in shares of BioMarin Pharmaceutical by 2.6% in the 2nd quarter. First Mercantile Trust Co. now owns 8,116 shares of the biotechnology company’s stock valued at $695,000 after acquiring an additional 206 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in shares of BioMarin Pharmaceutical by 4.0% in the 1st quarter. Janney Montgomery Scott LLC now owns 6,940 shares of the biotechnology company’s stock valued at $616,000 after acquiring an additional 268 shares during the period. 97.93% of the stock is currently owned by institutional investors.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus set a $108.00 target price on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Friday, September 13th. Wedbush reaffirmed an “outperform” rating and issued a $128.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, July 10th. Citigroup reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Thursday, May 23rd. BidaskClub raised shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $133.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, August 5th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $115.33.

In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $74.47, for a total transaction of $279,262.50. Following the sale, the director now directly owns 27,340 shares in the company, valued at approximately $2,036,009.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.90% of the company’s stock.

NASDAQ:BMRN traded up $0.27 during midday trading on Thursday, reaching $75.77. The stock had a trading volume of 397,049 shares, compared to its average volume of 955,794. The firm has a fifty day simple moving average of $75.31 and a two-hundred day simple moving average of $83.43. BioMarin Pharmaceutical Inc. has a 12-month low of $70.82 and a 12-month high of $106.74. The company has a quick ratio of 2.79, a current ratio of 4.11 and a debt-to-equity ratio of 0.28. The stock has a market cap of $13.53 billion, a P/E ratio of -229.61 and a beta of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative net margin of 7.19% and a negative return on equity of 3.12%. The firm had revenue of $388.00 million during the quarter, compared to analysts’ expectations of $415.03 million. During the same quarter last year, the business earned ($0.09) earnings per share. The business’s quarterly revenue was up 4.0% on a year-over-year basis. On average, sell-side analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.03 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Article: Capital Gains Distribution

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.